274676-47-0

Usage

Uses

Used in Pharmaceutical Industry:
1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI) is used as a potential pharmaceutical candidate for [specific application reason, if available] due to its unique chemical structure and potential biological activities. Its heterocyclic nature and the presence of nitrogen and carbon atoms in the fused ring system may contribute to its potential as a therapeutic agent or a building block in the development of new drugs.

Upstream product

• 1569-16-0 2-methyl-[1,8]naphthyridine 
• 1824-81-3 2-Amino-6-methylpyridine 
• 23612-57-9 (2-amino-3-pyridinyl)methanol 
• 67-63-0 isopropyl alcohol 
• 1292237-99-0 ethyl 3-[(6-methylpyridine-2-yl)amino]propionate 
• 1292955-81-7 C₉H₁₂N₂O 
• 55469-89-1 N-(6-methyl-[2]pyridyl)-β-alanine 
• 55469-90-4 7-methyl-2,3-dihydro-1,8-naphthyridin-4-(1H)one 
• 885276-99-3 2-amino-6-methylpyridine-3-carbaldehyde 
• 67-64-1 acetone 
• 855313-30-3 2-tert-butylamino-pyridine-3-carbaldehyde 
• 76293-30-6 N-tert-butyl-2-aminopyridine 
• 7521-41-7 2-Aminonicotinaldehyde 
• 504-29-0 2-aminopyridine 

Downstream Products

• 243641-37-4 tert-butyl 7-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate 
• 925889-81-2 tert-butyl 7-(2-methoxy-2-oxoethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate 
• 243642-19-5 ethyl (S)-3-phenyl-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-ethoxy]phenyl]butanoate 
• 243641-39-6 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol 
• 445490-61-9 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol 
• 445490-78-8 tert-butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(12H)-carboxylate 
• 445491-05-4 7-{2-[1-(1-biphenyl-4-yl-2-ethoxycarbonyl-ethyl)-1H-indol-5-yloxy]-ethyl}-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445491-22-5 7-(2-{1-[2-ethoxycarbonyl-1-(3-methoxy-phenyl)-ethyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445491-19-0 7-(2-{1-[2-ethoxycarbonyl-1-(2-methoxy-phenyl)-ethyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445491-25-8 7-(2-{1-[2-ethoxycarbonyl-1-(4-methoxy-phenyl)-ethyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445491-31-6 7-(2-{1-[1-(3-Chloro-phenyl)-2-ethoxycarbonyl-ethyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Pyrrolidine integrin regulator and application thereof

Disclosed are a compound as represented by formula I, and a racemate, a stereoisomer, a tautomer, an isotopic marker, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, and a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method therefor, and the medical use thereof. The structure of formula I is as follows:

Synthesis of Tetrahydroquinolines via Borrowing Hydrogen Methodology Using a Manganese PN3Pincer Catalyst

A straightforward and selective synthesis of 1,2,3,4-tetrahydroquinolines starting from 2-aminobenzyl alcohols and simple secondary alcohols is reported. This one-pot cascade reaction is based on the borrowing hydrogen methodology promoted by a manganese(I) PN3 pincer complex. The reaction selectively leads to 1,2,3,4-tetrahydroquinolines thanks to a targeted choice of base. This strategy provides an atom-efficient pathway with water as the only byproduct. In addition, no further reducing agents are required.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)

Ruthenium-Catalyzed Straightforward Synthesis of 1,2,3,4-Tetrahydronaphthyridines via Selective Transfer Hydrogenation of Pyridyl Ring with Alcohols

Through a ruthenium-catalyzed selective hydrogen transfer coupling reaction, a novel straightforward synthesis of 1,2,3,4-tetrahydronaphthyridines from o-aminopyridyl methanols and alcohols has been developed. The synthetic protocol proceeds in an atom- a

2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

Facile preparation of thiophene C2-ethers using the Mitsunobu reaction

The preparation of thiophene ethers generally requires forcing conditions thus limiting the choice of alkyl substituent. Herein, we report the first successful generally applicable conditions for the selective O-alkylation of 2(5H)-thiophenone.

Non-peptidic αvβ3 antagonists containing indol-1-yl propionic acids

We describe the synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ 3. Indol-1-yl propionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified.

NOVEL PROCESSES FOR THE SYNTHESIS OF CYCLOPROPYL COMPOUNDS

This invention relates to processes for the preparation of cyclopropyl compounds of Formula: (I) wherein: x is an integer selected from the group consisting of 0, 1 and 2; R and R are independently selected from the group consisting of H, C1-C6 alkyl, and halo; and R, R, R, R and R are independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, and halo.